In 2011, the federal government began offering financial rewards for providers to implement electronic health records (EHRs) in caring for their Medicare and Medicaid patients. For eligible doctors, these “meaningful use” incentives could provide you with extra income of up to $44,000 over five years in Medicare incentives and $63,750 in Medicaid incentives over six years.
Rebecca Twersky-Kengmana, MD
Psychiatrist in private practice, New York, NY
Dr. Twersky-Kengmana has disclosed that she has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
It’s important to understand what bias is not. Bias is not fraud, as it does not involve intentional prejudice. Bias is also not random error, which creates deviation in results strictly by chance, and can be mitigated with a large enough study sample. Put simply, bias has to do with the unintentional skewing of results due to human failings such as poor trial design or unconscious wishes for desirable outcomes.
Joshua Sonkiss, MD
Medical director, Behavioral Health Unit, Fairbanks Memorial Hospital, Fairbanks, AK
Dr. Sonkiss has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
As a physician, you’re expected to practice evidence-based medicine. But how can anyone keep up with the latest research?
Glen Spielmans, PhD
Associate professor of psychology, Metropolitan State University, St. Paul, MN
Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.
After a psychiatric drug is approved by the Food and Drug Administration (FDA), a marketing juggernaut often follows, trying to convince us that the newly approved drug offers substantial benefits for treating a mental disorder. But how does the FDA determine whether to approve a drug? What follows is a breakdown of the process.
Bruce Cuthbert, PhD
Director, Division of Adult Translational Research and Treatment Development, NIMH
Dr. Cuthbert has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Bruce Cuthbert, PhD, the head of the NIMH’s new Research Domain Criteria (RDoC) program, explains how this new way of funding and conducting research in psychiatry is revolutionizing the field.
Concerns about the safety of psychiatric medications during pregnancy are common among psychiatrists and patients alike. In many cases, one must weigh the risks of a medication to mother or child against the risks inherent in untreated mental illness. Recent research, however, lends support to the growing data about the safety of antidepressant medications in pregnancy.
Tisa Adkinson, DO
Child and Adolescent and Addiction Psychiatrist, CARES, the Child and Family Institute, New York, NY
Dr. Adkinson has disclosed that she has no relevant relationships or commercial interests in any companies related to this educational activity.Pavan Madan, MD
Child and Adolescent Psychiatry Fellow, Mount Sinai St. Luke’s-Roosevelt Hospital Center, New York, NY
Dr. Madan has disclosed that he has no relevant relationships or commercial interests in any companies related to this educational activity.
Considering the increased efforts to legalize marijuana in many states, greater public awareness of marijuana and its potential medicinal uses, and new research on cannabis and its constituents, it is essential that psychiatrists understand some of its proposed benefits—and fundamental risks.